Half-yearly Report
Half-yearly Report
August 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), (“Shire” / the “Company”/ the “Group”) in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, is publishing its Half-yearly Report for the six months ended June 30, 2018.
On July 31, 2018, the Group announced its results for the same period.
Stephen Williams
Deputy Company Secretary
For further information please contact:
| Investor Relations | ||
| Christoph Brackmann | [email protected] | +41 41 288 41 29 |
| Sun Kim | [email protected] | +1 617 588 8175 |
| Scott Burrows | [email protected] | +41 41 288 41 95 |
| Media | ||
| Katie Joyce | [email protected] | +1 781 482 2779 |
NOTES TO EDITORS
About Shire
Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, Ophthalmics, and Oncology.
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.